Mazor Robotics Ltd – (MZOR) Downgraded to Underweight at Barclays PLC
Mazor Robotics Ltd – (NASDAQ:MZOR) was downgraded by stock analysts at Barclays PLC from an “equal weight” rating to an “underweight” rating in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. They presently have a $34.00 price objective on the medical instruments supplier’s stock, down from their prior price objective of $55.00. Barclays PLC’s target price points to a potential downside of 36.81% from the stock’s current price.
Several other equities research analysts also recently commented on MZOR. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics Ltd – in a research note on Thursday, July 6th. Zacks Investment Research downgraded shares of Mazor Robotics Ltd – from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services set a $54.00 target price on shares of Mazor Robotics Ltd – and gave the company a “buy” rating in a research note on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $37.67.
Mazor Robotics Ltd – (MZOR) traded down 1.70% during trading on Thursday, reaching $53.81. 655,698 shares of the company’s stock traded hands. Mazor Robotics Ltd – has a 12 month low of $20.19 and a 12 month high of $59.59. The firm’s 50 day moving average is $49.50 and its 200 day moving average is $40.32. The company’s market cap is $1.30 billion.
Mazor Robotics Ltd – (NASDAQ:MZOR) last issued its earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.09. Mazor Robotics Ltd – had a negative net margin of 23.79% and a negative return on equity of 23.41%. The firm had revenue of $15.46 million during the quarter, compared to the consensus estimate of $15.38 million. During the same quarter in the prior year, the firm earned ($0.09) earnings per share. The business’s quarterly revenue was up 86.7% on a year-over-year basis. Analysts anticipate that Mazor Robotics Ltd – will post ($0.77) EPS for the current year.
Several hedge funds have recently modified their holdings of the company. Credit Suisse AG increased its position in shares of Mazor Robotics Ltd – by 66.5% during the first quarter. Credit Suisse AG now owns 330,000 shares of the medical instruments supplier’s stock worth $9,824,000 after acquiring an additional 131,804 shares in the last quarter. Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Mazor Robotics Ltd – during the second quarter worth $8,014,000. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Mazor Robotics Ltd – by 5.4% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 180,180 shares of the medical instruments supplier’s stock worth $6,231,000 after acquiring an additional 9,276 shares in the last quarter. Nepsis Capital Management Inc. bought a new stake in shares of Mazor Robotics Ltd – during the second quarter worth $5,873,000. Finally, Driehaus Capital Management LLC bought a new stake in shares of Mazor Robotics Ltd – during the first quarter worth $3,410,000. 25.92% of the stock is owned by institutional investors.
Mazor Robotics Ltd – Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.